Health Care · Surgical & Medical Instruments & Apparatus

AORT ARTIVION, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 784199100 filings
Russell 2000

AORT at a glance

ARTIVION, INC. (AORT, SEC CIK 784199) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ARTIVION, INC. (AORT) reported revenue of $441.3 million (up 13.6% from FY2024) and net income of $9.8 million. Diluted EPS was $0.21.
  • As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding ARTIVION, INC. (AORT) shares worth $498.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by GREEN ANDREW M on September 10, 2026 of 11,480 shares at $24.97 per share.
  • In the last 90 days, AORT insiders reported 0 open-market purchases ($0) and 3 open-market sales ($503K) on Form 4, a net sale of $503K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$441.3M
+13.6% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$503K
13F holders
31 funds
$498.4M · +1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Manufacturer and distributor of medical devices and implantable human tissues for cardiac and vascular surgery, focusing on aortic disease treatment
  • New product launch: Arcevo™ LSA Hybrid Stent Graft System introduced in EMEA and APAC in 2025, with US PMA trial ongoing, plus PerClot® hemostatic powder manufacturing started Q2 2023
  • Strategic shift: Expanded global reach with new international markets including China and Brazil, enhanced pipeline with next-generation devices like Arcevo LSA and NEO EDE custom version
  • Quantitative metric: FDA granted humanitarian device exemption for AMDS hybrid prosthesis in Dec 2024 enabling limited US commercial distribution before full PMA approval expected in 2026
  • Noteworthy fact: CMS created a new unique DRG procedure code for AMDS effective Oct 1, 2025, reflecting recognition of its distinct hospital resource use for complex aortic arch repair

Risk Factors

  • Regulatory risk: Italian medical device overpayment repayment exposure $2.3M for 2019–2025 period under Ministerial Decree, potential further government assessment
  • Geopolitical risk: NEXUS products solely made in Israel amid Middle East conflicts, risking supply disruption from war, sanctions, or export controls
  • Operational risk: Single-source suppliers for BioGlue components and On-X grafts could halt manufacturing if suppliers face issues, risking product availability
  • Competitive risk: Facing competition from Baxter, J&J’s Ethicon, Medtronic, Abbott with greater resources and stronger regulatory approval track records
  • Financial risk: Acquisition-related impairments including Endospan loan and option write-downs affecting market value and risking future goodwill impairments

Management Discussion & Analysis

  • Revenue $441.3M in 2025, up 14% YoY from $388.5M in 2024; constant currency increase 13%
  • Gross margin 64% in 2025, flat YoY despite 14% gross margin dollar growth to $284.2M
  • Best segment: Aortic stent grafts $159.4M +29% YoY; Worst: Preservation services $95.5M -3% YoY
  • Operating expenses increased 25% to $226.5M driven by sales/marketing and cybersecurity costs; R&D up 9% to $31.0M
  • Cash & equivalents $64.9M at year-end; $220M nominal debt outstanding; no specific buyback or dividend data given
  • Management notes ongoing seasonality, cybersecurity incident impacts in 2024; AMDS product commercial launch in US anticipated in 2026

AI summary of the AORT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Italian medical-device repayment exposure, approximately $2.3 million for 2019–2025, pending government assessment
  • Endospan acquisition completed May 18, 2026, adding NEXUS manufacturing concentration in Herzliya, Israel amid regional conflict
  • CryoValve SGPV reclassification risk, potential Class III designation could make continued processing commercially infeasible
  • FDA and other regulatory review delays, reduced federal staffing could delay clinical trials and product approvals
  • Variable-rate indebtedness, covenant breach could accelerate repayment and permit foreclosure on substantially all US assets

Management Discussion & Analysis

  • Revenue $123.8M, up 9% YoY from $113.4M
  • Gross margin 61% vs 66% YoY, pressured by higher costs and unfavorable mix
  • Best performer: Other revenue $4.6M, up 93%; worst: Surgical sealants $18.9M, flat YoY
  • Cash $48.4M, operating cash flow $(4.7)M vs $20.3M YoY
  • Endospan acquisition used $116.7M; $150.0M term loan raised; PerClot manufacturing expected to end by year-end 2026

AI summary of the AORT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results for the period ended September 30, 2026 announced on November 5, 2026
  • Detailed financial performance and management commentary available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $123.8M, up 9% constant currency, led by On-X growth 13% and aortic stent grafts growth 12%
  • GAAP net loss $(7.9)M, or $(0.16) per share, versus $6.5M profit and $0.13 per share
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Artivion announced second-quarter fiscal 2026 financial results for the period ended June 30, 2026
  • Press release dated August 6, 2026 contains the substantive revenue, earnings, and outlook information

Item EX-99.1: Item EX-99.1

  • Q2 revenue $125.8M, up 11% GAAP and 9% constant currency, led by On-X growth 18% and stent graft growth 12%
  • GAAP net loss $(13.5)M, or $(0.28) per share, versus $1.3M profit; non-GAAP EPS declined to $0.13 from $0.24
Filed May 18, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Artivion completed its acquisition of Endospan, an Israeli aortic-device developer
  • Endospan’s Nexus™ product expands Artivion’s portfolio for treating aortic instability

Item 8.01: Other Events

  • Endospan acquisition closed May 18, 2026, adding its NEXUS™ Aortic Arch Stent Graft System to Artivion’s portfolio
  • Net cash purchase price approximately $131.3 million after offsetting intercompany loans

AI summaries of AORT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AORT

Don't miss the next AORT filing

  • Alerts as it files. A push when AORT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AORT, by share count.
  • Ask anything. An AI agent that reads every AORT filing and answers with sources.

AORT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
GREEN ANDREW MSellSep 10, 2026$24.97
GREEN ANDREW MSellSep 3, 2026$26.02
GREEN ANDREW MSellSep 2, 2026$27.27
Mackin James PSellAug 19, 2026$28.95
GREEN ANDREW MSellAug 14, 2026$28.55
Berry Lance ASellAug 14, 2026$28.55
Holloway Jean FSellAug 12, 2026$28.49
GREEN ANDREW MMJun 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$388.5M$441.3M
Gross Profit-$248.8M$284.2M
Operating Income-$38.9M$33.7M
Net Income--$13.4M$9.8M
Gross Margin-64.0%64.4%
Op. Margin-10.0%7.6%
Net Margin--3.4%2.2%
Balance Sheet
Total Assets$792.4M$789.1M$884.8M
Equity$281.8M$276.2M$448.2M
ROE--4.8%2.2%
Per Share
EPS-$-0.32$0.21
Cash Flow
Operating CF-$22.2M$39.9M
CapEx-$11.2M$39.0M

Source: XBRL data in ARTIVION, INC. (AORT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AORT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AORT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202631$498.4M
Q2 202630$493.5M
Q1 202629$758.2M
Q4 202528$961.7M
Q3 202528$852.6M
Q2 202528$590.9M
Q1 202526$327.7M
Q4 202421$248.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 221 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AORT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 6, 2026Analysis
8-KNov 5, 2026Analysis-
4Sep 11, 2026--
4Sep 4, 2026--
4Aug 20, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 12, 2026--
10-QAug 7, 2026Analysis
8-KAug 6, 2026Analysis-
4Jun 15, 2026--
4Jun 4, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 19, 2026-
8-KMay 18, 2026Analysis
8-KMay 15, 2026Analysis
10-QMay 8, 2026Analysis
8-KMay 7, 2026Analysis

Related Health Care companies

All Health Care →

AORT SEC filings: frequently asked questions

Are AORT insiders buying or selling?

In the last 90 days, ARTIVION, INC. (AORT) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $502,993 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold AORT stock?

As of September 30, 2026, the largest ARTIVION, INC. (AORT) holders among the 13F filers tracked by SignalX were BlackRock ($167.7 million), Morgan Stanley ($60.4 million), Vanguard Capital Management LLC ($47.1 million), State Street Corp ($45.5 million), Citadel Advisors LLC ($26.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AORT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ARTIVION, INC. (AORT) reported revenue of $441.3 million (up 13.6% from FY2024) and net income of $9.8 million. Diluted EPS was $0.21. The figures come from the XBRL data in the 10-K.

What are the main risks in AORT's latest 10-K?

In the 10-K filed February 18, 2026, ARTIVION, INC. (AORT) flagged: Regulatory risk: Italian medical device overpayment repayment exposure $2.3M for 2019–2025 period under Ministerial Decree, potential further government assessment. Geopolitical risk: NEXUS products solely made in Israel amid Middle East conflicts, risking supply disruption from war, sanctions, or export controls. (AI summary of the Risk Factors section.)

What did AORT report in its latest 8-K?

ARTIVION, INC. (AORT) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for the period ended September 30, 2026 announced on November 5, 2026.

What are the latest AORT SEC filings?

ARTIVION, INC. (AORT) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 11, 2026.

What is AORT's SEC CIK number?

ARTIVION, INC. (AORT)'s SEC Central Index Key (CIK) is 784199. EDGAR lists every AORT filing under that number.

Ask anything about AORT

The research agent reads AORT's filings, financials, insider trades and 13F holders, then answers with sources.